Annexon Biosciences (ANNX) Reiterated at Overweight by Cantor Fitzgerald

Cantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating on Annexon Biosciences (NASDAQ: ANNX).

The anayst commented, "We caught up with ANNX management to discuss the regulatory activity and the MAA filing for tanruprubart (ANX005) in Guillain-Barré syndrome (GBS), and the upcoming ARCHER II P3 vonaprument (ANX007) readout in geographic atrophy (GA). ANNX reached a key regulatory milestone with the submission of an MAA in the EU for tanruprubart in GBS, marking the company’s first regulatory filing that we believe is supported by a robust dataset."

For an analyst ratings summary and ratings history on Annexon Biosciences click here. For more ratings news on Annexon Biosciences click here.

Shares of Annexon Biosciences closed at $6.19 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating